Bay City Capital is a life sciences investment firm established in 1997, managing $1.3 billion across five venture capital funds. The company invests globally in a diverse portfolio of over 100 life sciences companies, targeting sectors such as biopharmaceuticals, medical devices, and healthcare IT. Bay City Capital's strategy includes seed to public company investments, leveraging its extensive network and expertise to support innovation and growth in the life sciences industry.
Recent Transactions involving Bay City Capital
| Deal | Target | Platform | Buyer | Industry |
|---|---|---|---|---|
Novo Seeds Portfolio Company Galecto Announces Merger with US based PharmAkea |
PharmAkea |
Galecto |
Novo HoldingsHBM Healthcare InvestmentsYsios CapitalSunstone CapitalBay City CapitalOrbiMedSeventure PartnersM VenturesBristol Myers SquibbMaverick Ventures |
The Lower and Middle Market M&A Platform
See how PrivSource can help you close more deals.
Learn more →